WO2000064464A8 - Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisations - Google Patents
Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisationsInfo
- Publication number
- WO2000064464A8 WO2000064464A8 PCT/US1999/007384 US9907384W WO0064464A8 WO 2000064464 A8 WO2000064464 A8 WO 2000064464A8 US 9907384 W US9907384 W US 9907384W WO 0064464 A8 WO0064464 A8 WO 0064464A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- specific
- ganglioside
- rat
- rat ganglioside
- derivatives
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108091005461 Nucleic proteins Proteins 0.000 title 1
- 150000002270 gangliosides Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108020005544 Antisense RNA Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000003184 complementary RNA Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000050 nutritive effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une alpha1→2fucosyltransférase spécifique du ganglioside GM1 murin, ainsi que des séquences nucléotidiques d'une alpha1→2fucosyltransférase spécifique du ganglioside GM1 murin, des séquences aminoacides de sa protéine codée (notamment un peptide ou un polypeptide), et des dérivés de celle-ci. Cette invention concerne également des fragments (et des dérivés et des analogues de ceux-ci) qui comprennent un domaine de l'alpha1→2fucosyltransférase spécifique du ganglioside GM1 murin présentant une activité catalytique. L'invention concerne également des méthodes de production de cette alpha1→2fucosyltransférase spécifique du ganglioside GM1 murin et des dérivés et des analogues de celle-ci (obtenus par exemple par des moyens de recombinaison), ainsi que des méthodes permettant d'inhiber la fonction de l'alpha1→2fucosyltransférase spécifique du ganglioside GM1 murin (par exemple au moyen de l'ARN antisens). L'invention concerne par ailleurs des méthodes d'exploitation commerciale de cette alpha1→2fucosyltransférase spécifique du ganglioside GM1 murin, méthodes qui permettent d'élaborer des compositions de fucosyle-saccharide. Cette invention concerne enfin des applications de ces compositions, notamment comme additifs dans des compositions nutritives humaines ou comme agents immunothérapeutiques pour lutter contre le cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1999/007384 WO2000064464A1 (fr) | 1999-04-23 | 1999-04-23 | Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1999/007384 WO2000064464A1 (fr) | 1999-04-23 | 1999-04-23 | Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000064464A1 WO2000064464A1 (fr) | 2000-11-02 |
| WO2000064464A8 true WO2000064464A8 (fr) | 2001-02-08 |
Family
ID=22272499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/007384 WO2000064464A1 (fr) | 1999-04-23 | 1999-04-23 | Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisations |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2000064464A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6329078B2 (ja) * | 2011-11-30 | 2018-05-23 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 生物学的モニタリングのためのアネキシンｖのマイクロ粒子ポリペプチドに対するｇｍ１ガングリオシドの比 |
-
1999
- 1999-04-23 WO PCT/US1999/007384 patent/WO2000064464A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000064464A1 (fr) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000031235A3 (fr) | Sequences nucleotidiques et proteiques de gene nogo et procedes reposant sur ces sequences | |
| DE60033138D1 (de) | Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren | |
| WO2001029222A3 (fr) | Polypeptides ayant une activite phospholipase b et acides nucleiques codant ces derniers | |
| DE69833784D1 (de) | Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren | |
| DE69837475D1 (de) | Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren | |
| WO2002070549A3 (fr) | Polypeptides chimeriques d'albumine serique et utilisations de ces derniers | |
| WO2003050236A3 (fr) | Genes humains et produits d'expression geniques isoles d'une prostate humaine | |
| WO1998011234A3 (fr) | Proteines kinases humaines | |
| CA2202519A1 (fr) | Clonage, expression et caracterisation d'une nouvelle forme de phosphatidylinositol-3-kinase | |
| AU4608097A (en) | Carboxypeptidases from aspergillus oryzae and nucleic acids encoding same | |
| WO2000064464A8 (fr) | Acides nucleiques et proteines d'une alpha1→2fucosyltransferase specifique du ganglioside gm1 murin, et leurs utilisations | |
| WO2000041509A3 (fr) | Polypeptides possedant une activite de phosphatase acide et acides nucleiques codant pour ceux-ci | |
| WO2001036478A3 (fr) | Methodes et compositions se rapportant a des polypeptides et a des polynucleotides similaires au facteur bactericide augmentant la permeabilite | |
| WO1999063094A3 (fr) | Sequences nucleotidiques et proteiques gpr1 et methodes y relatives | |
| WO2005105838A3 (fr) | Canal ionique | |
| WO2002055700A3 (fr) | Genes humains et produits d'expression genetique isoles de la prostate humaine | |
| WO2002064827A3 (fr) | Acides nucleiques du gene humain abca12, vecteurs contenant ces acides nucleiques, et utilisations associees | |
| AU7645400A (en) | Polypeptides having glucanotransferase activity and nucleic acids encoding same | |
| WO2003025182A1 (fr) | Adn de surexpression d'une hormone de croissance et utilisation | |
| EP1536010A4 (fr) | Medicaments destines a la prevention et au traitement du cancer | |
| EP0897984A3 (fr) | Gène de deshydrogenase de sorbitol | |
| WO2003099995A3 (fr) | Orthologue murin du gene humain de la proteine disc-1 (disrupted in schizophrenia 1 gene) | |
| WO1999043834A3 (fr) | Proteine constituant un ligand de la p-selectine et proteines de fusion tetrameriques | |
| WO2002029054A1 (fr) | Nouvelle proteine, son procede de production et son utilisation | |
| CA2360530A1 (fr) | Nucleoproteine humaine possedant un domaine ww et polynucleotide codant cette nucleoproteine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: C1 Designated state(s): CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| CFP | Corrected version of a pamphlet front page | ||
| CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 44/2000 UNDER (51) REPLACE "C12N 6/02" BY "C12N 5/02" |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |